Physician profile
Aksel Narvaez
NPI 1154090744
$3,311.21
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $159 · 2022: $815 · 2023: $1,256 · 2024: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,266 · Education: $71.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,265.69 |
| Education | $71.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $737.23 | 2021-2024 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $658.54 | 2022-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $461.02 | 2022-2024 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $298.34 | 2022-2023 | Uzedy, Austedo Xr |
| Abbvie INC. | $249.18 | 2022-2024 | |
| Novo Nordisk INC | $149.92 | 2023-2024 | Wegovy |
| Axsome Therapeutics, INC. | $128.90 | 2023 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2021 | |
| Lundbeck LLC | $114.44 | 2021-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $112.87 | 2023-2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $72.88 | 2022-2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $61.41 | 2022-2024 | Rexulti, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $59.67 | 2022-2023 | Qelbree |
| Sunovion Pharmaceuticals INC. | $44.09 | 2022 | |
| Eisai INC. | $19.53 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $18.19 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aksel Narvaez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.